ARTICLE | Strategy
Agouron, Syntex look ahead to the clinic
June 14, 1993 7:00 AM UTC
Agouron, Syntex look ahead to the clinic A new collaboration between Agouron Pharmaceuticals Inc. (AGPH) and Syntex Corp. should provide products ready for clinical trials in both arthritis and cancer within three to four years, according to Peter Johnson, president and CEO of AGPH.
The collaboration announced last week will focus on discovery and development of selective inhibitors of one or more members of the class of enzymes called matrix metalloproteases. MMPs are implicated in the degradation of connective tissue in several diseases, including osteoarthritis and rheumatoid arthritis, and may play a role in tumor metastasis. ...